Related Experiment Video

Updated: Oct 1, 2025

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

9.9K

Promalignant effects of antiangiogenics in the tumor microenvironment

Felix Peix1, Oriol Casanovas1

  • 1Tumor Angiogenesis Group. ProCURE, Catalan Institute of Oncology, OncoBell, IDIBELL, Barcelona, Spain.

Seminars in Cancer Biology
|March 6, 2022
PubMed

Insights

Antiangiogenic therapies targeting tumor vasculature show modest benefits and can increase cancer aggressiveness. Targeting multiple cell receptors simultaneously may offer a more effective treatment to prevent metastasis.

Area of Science:

  • Oncology
  • Cancer Biology
  • Tumor Microenvironment

Background:

  • Antiangiogenic therapies aim to inhibit tumor vascularization, reducing nutrient and oxygen supply.
  • Limitations include modest survival benefits and increased tumor invasion and metastasis.
  • Tumor microenvironment changes (hypoxia, stress, acidification) drive aggressiveness.

Purpose of the Study:

  • To explore strategies to overcome limitations of antiangiogenic therapies.
  • To investigate the role of receptor tyrosine kinases and extracellular matrix sensors in tumor progression.
  • To evaluate the potential of targeting multiple cellular receptors for improved cancer treatment.

Main Methods:

  • Review of current antiangiogenic therapy strategies and their outcomes.
  • Analysis of cellular signaling pathways activated by tumor microenvironment changes.
  • Investigation of receptor tyrosine kinases (e.g., c-Met) and matrix-sensing receptors (integrins, proteoglycans).

Main Results:

  • Inhibition of c-Met shows promise in reducing tumor invasiveness and improving survival.
  • Extracellular matrix receptors activate signaling pathways promoting tumor remodeling.
  • Simultaneous targeting of multiple receptors may prevent malignant side effects.

Conclusions:

  • Targeting tumor vasculature alone is insufficient due to adaptive resistance mechanisms.
  • Simultaneous inhibition of multiple signaling pathways (e.g., c-Met and matrix receptors) is a promising therapeutic strategy.
  • Combination therapies could enhance treatment efficacy and prevent cancer metastasis.
Keywords:
Antiangiogenic therapyExtracellular matrixMembrane receptorsTumor invasivenessTumor microenvironment

More Related Videos

Isolation and Culture Expansion of Tumor-specific Endothelial Cells10:15

Isolation and Culture Expansion of Tumor-specific Endothelial Cells

Published on: October 14, 2015

11.3K
Assessing Tumor Microenvironment of Metastasis Doorway-Mediated Vascular Permeability Associated with Cancer Cell Dissemination using Intravital Imaging and Fixed Tissue Analysis09:42

Assessing Tumor Microenvironment of Metastasis Doorway-Mediated Vascular Permeability Associated with Cancer Cell Dissemination using Intravital Imaging and Fixed Tissue Analysis

Published on: June 26, 2019

8.9K

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.0K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K